Cetin Esra Can, Guven Suleyman, Sal Hidayet, Guvendag Guven Emine Seda, Mentese Ahmet
Karadeniz Technical University School of Medicine, Department of Obstetrics and Gynecology, Trabzon, Turkey.
Program of Medical Laboratory Techniques, Vocational School of Health Sciences, Karadeniz Technical University, Trabzon, Turkey.
Prz Menopauzalny. 2021 Jun;20(2):76-80. doi: 10.5114/pm.2021.106089. Epub 2021 May 23.
To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women.
Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planned to have HT for menopausal symptoms were enrolled in this prospective study. The serum İMA levels were recorded before and after (3 months, 6 months, 12 months later) hormone treatment (2 mg estradiol hemihydrate).
The mean age of women was 47.60 ± 2.34 years. The mean serum IMA levels were 0.610 ± 0.096 absorbance units (ABSU) at the beginning and 0.484 ± 0.080 ABSU after 3 months of hormone therapy. Following 6 months of hormone therapy, serum IMA level was 0.546 ± 0.075, and reached 0.580 ± 0.089 ABSU following 12 months of therapy.
These findings suggest that HT may not block the menopause induced ischemia process. Although HT had a positive effect on serum IMA levels following 3 months' use, serum IMA levels returned to baseline levels after 12 months' use. Based on this study's findings, long-term use of HT may not have a positive effect on cardiovascular disease protection.
评估激素疗法（HT）对健康绝经后女性血清缺血修饰白蛋白（IMA）水平的影响。
本前瞻性研究纳入了30名手术绝经后女性，她们在1年期间入住我们的绝经专科门诊，被诊断为绝经，并计划因绝经症状接受激素疗法。在激素治疗（2mg半水合雌二醇）前以及治疗后（3个月、6个月、12个月后）记录血清IMA水平。
女性的平均年龄为47.60±2.34岁。激素治疗开始时血清IMA水平的平均值为0.610±0.096吸光度单位（ABSU），治疗3个月后为0.484±0.080ABSU。激素治疗6个月后，血清IMA水平为0.546±0.075，治疗12个月后达到0.580±0.089ABSU。
这些发现表明，激素疗法可能无法阻断绝经诱导的缺血过程。虽然激素疗法在使用3个月后对血清IMA水平有积极影响，但使用12个月后血清IMA水平恢复到基线水平。基于本研究结果，长期使用激素疗法可能对心血管疾病保护没有积极作用。
